KR20230097118A - 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 - Google Patents

자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 Download PDF

Info

Publication number
KR20230097118A
KR20230097118A KR1020237018007A KR20237018007A KR20230097118A KR 20230097118 A KR20230097118 A KR 20230097118A KR 1020237018007 A KR1020237018007 A KR 1020237018007A KR 20237018007 A KR20237018007 A KR 20237018007A KR 20230097118 A KR20230097118 A KR 20230097118A
Authority
KR
South Korea
Prior art keywords
patient
nmosd
antibody
vib551
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237018007A
Other languages
English (en)
Korean (ko)
Inventor
드웨이 쉬
존 래치포드
엘리제르 카츠
윌리엄 리스
Original Assignee
비엘라 바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비엘라 바이오, 인크. filed Critical 비엘라 바이오, 인크.
Publication of KR20230097118A publication Critical patent/KR20230097118A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237018007A 2020-10-29 2021-10-29 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용 Pending KR20230097118A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063107182P 2020-10-29 2020-10-29
US63/107,182 2020-10-29
US202163143541P 2021-01-29 2021-01-29
US63/143,541 2021-01-29
US202163178286P 2021-04-22 2021-04-22
US63/178,286 2021-04-22
PCT/US2021/057443 WO2022094334A1 (en) 2020-10-29 2021-10-29 Use of an anti-cd19 antibody to treat autoimmune disease

Publications (1)

Publication Number Publication Date
KR20230097118A true KR20230097118A (ko) 2023-06-30

Family

ID=81384348

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237018007A Pending KR20230097118A (ko) 2020-10-29 2021-10-29 자가면역 질환을 치료하기 위한 항-cd19 항체의 사용

Country Status (10)

Country Link
US (1) US20230287114A1 (https=)
EP (1) EP4237447A4 (https=)
JP (1) JP2023549075A (https=)
KR (1) KR20230097118A (https=)
AU (1) AU2021368769A1 (https=)
CA (1) CA3197022A1 (https=)
IL (1) IL302294A (https=)
MX (1) MX2023004794A (https=)
TW (1) TW202233676A (https=)
WO (1) WO2022094334A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022006283A2 (en) * 2020-06-30 2022-01-06 Viela Bio, Inc. Methods of treating neuromyelitis optica spectrum disorder
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
AU2020263418A1 (en) * 2019-04-24 2021-11-11 Viela Bio, Inc. Use of an anti-CD19 antibody to treat autoimmune disease
WO2022006283A2 (en) * 2020-06-30 2022-01-06 Viela Bio, Inc. Methods of treating neuromyelitis optica spectrum disorder

Also Published As

Publication number Publication date
AU2021368769A1 (en) 2023-06-08
US20230287114A1 (en) 2023-09-14
TW202233676A (zh) 2022-09-01
WO2022094334A1 (en) 2022-05-05
EP4237447A1 (en) 2023-09-06
CA3197022A1 (en) 2022-05-05
IL302294A (en) 2023-06-01
JP2023549075A (ja) 2023-11-22
AU2021368769A9 (en) 2024-05-30
MX2023004794A (es) 2023-09-15
EP4237447A4 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
Prasad et al. What you need to know about AQP4, MOG, and NMOSD
Wingerchuk Neuromyelitis optica spectrum disorders
US20230287114A1 (en) Use of an anti-cd19 antibody to treat autoimmune disease
KR20240107372A (ko) 사트랄리주맙을 사용하는 중추 신경계(cns)의 탈수초화 질환의 치료
KR20220004113A (ko) 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도
CN113574071A (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
Duchow et al. Emerging drugs for the treatment of neuromyelitis optica
Gensicke et al. Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
Valencia-Sanchez et al. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders: C. Valencia-Sanchez et al.
Tenembaum Treatment of multiple sclerosis and neuromyelitis optica in children and adolescents
EP4682171A2 (en) Ofatumumab for treating ms while maintaining serum igg
CN116322765A (zh) 用于用奥瑞珠单抗治疗多发性硬化症的方法
WO2025221479A1 (en) Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors
KR20230030642A (ko) 시신경척수염 스펙트럼 장애를 치료하는 방법
EP4034885A1 (en) Method for determining potency of therapeutic anti-clever-1 antibody
JP2023504209A (ja) 視神経脊髄炎スペクトラム障害の治療のための抗ｃ５抗体
HK40096777A (zh) 使用抗cd19抗体治疗自身免疫性疾病
JP2024518410A (ja) 重症筋無力症を治療するための抗ｃｄ１９抗体の使用
CN116583538A (zh) 使用抗cd19抗体治疗自身免疫性疾病
Beyer et al. Neuromyelitis optica in a patient with an early onset demyelinating episode: clinical and autoantibody findings
Lorefice et al. Monoclonal antibodies: a target therapy for multiple sclerosis
RU2809565C2 (ru) Антитела к CD38 и фармацевтические композиции на их основе для лечения аутоиммунного заболевания, опосредованного аутоантителами
Fan et al. Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab
EA052907B1 (ru) Применение антитела к cd19 для лечения миастении гравис

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241029

Comment text: Request for Examination of Application